Reading the tape
NASDAQ: VCEL
Vericel Corporation
Healthcare · Biotechnology
Market Cap
$1.85B
52w High
$45.97
52w Low
$28.95
P/E
111.42
Volume
2.84K
Outstanding Shares
50.93M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -7.06%Revenue (TTM): 16.45%FCF (TTM): -20.98%P/FCF: 37th pct
What changed
The stock fell 7.06% over the last year. Revenue grew 16.45% over the trailing twelve months. Operating margin moved from 1.9% to 4%. Free cash flow declined 20.98% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 4%. A decisive move in revenue — currently up 16.45% — would be the clearest signal to resolve the ambiguity.
Company profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
CEODominick C. Colangelo
SectorHealthcare
IndustryBiotechnology
Employees357
IPO dateFeb 4, 1997
Valuation
Forward P/E—
EV/EBITDA60.08
Enterprise value$1.82B
Stock splits
Oct 16, 2013↓ Reverse
Every 20 shares became 1
Feb 18, 2010↓ Reverse
Every 8 shares became 1
Profitability & growth
Revenue growth23.27%
Gross margin74.42%▲2.58%vs FY2024
Operating margin4%▲109.86%vs FY2024
ROE4.66%▲31.24%vs FY2024
Analyst consensus
RatingBuy
Target price$44.00▲20.95%
9
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.15 · Revenue est $63.68M
View